MDM2 oncogene as a target for cancer therapy: An antisense approach.
Haowei Wang(Shanghai Jiao Tong University), R Zhang(University of Alabama at Birmingham), Patsy G. Oliver(Molecular Oncology (United States)), Sudhir Agrawal(Idera Pharmaceuticals (United States)), Long P. Le(Brigham and Women's Hospital), Lei Chen(Astrophysique Relativiste, Théories, Expériences, Métrologie, Instrumentation, Signaux), Xiaorong Zeng(Ministry of Education of the People's Republic of China), Wei Zhou(Broad Institute), J Chen(University of Alabama at Birmingham)
Cited by 82
Related Papers
GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases
|Nature Biotechnology|2014|2.3k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
Towards a general-purpose foundation model for computational pathology
|Nature Medicine|2024|1.1k